A Risk-Benefit Assessment of Sildenafil in the Treatment of Erectile Dysfunction

被引：0

作者：

Dinko Vitezic

机构：

[1] University of Rijeka Medical School,Clinical Pharmacology, Department of Pharmacology

[2] and Department for Science and Clinical Pharmacology,undefined

[3] University Hospital Centre Rijeka,undefined

来源：

Drug Safety | 2001年 / 24卷

关键词：

Erectile Dysfunction; Phentolamine; Priapism; Alprostadil; Intracavernosal Injection;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Sildenafil is an oral treatment for erectile dysfunction (ED). It acts as an inhibitor of 3′,5′-cyclic guanosine monophosphate-phosphodiesterase type 5. An effective treatment for ED is required to produce an erectile response sufficient for satisfactory sexual performance. This has been documented for sildenafil in men with ED of differing aetiologies and baseline severity in various types of clinical trials.

引用

页码：255 / 265

页数：10

共 50 条

[31] A Risk-Benefit Assessment of Buspirone in the Treatment of Anxiety Disorders
John C. Pecknold
Drug Safety, 1997, 16 : 118 - 132
[32] A RISK-BENEFIT ASSESSMENT OF CARVEDILOL IN THE TREATMENT OF CARDIOVASCULAR DISORDERS
LOUIS, WJ
KRUM, H
CONWAY, EL
DRUG SAFETY, 1994, 11 (02) : 86 - 93
[33] A RISK-BENEFIT ASSESSMENT OF DRUGS USED IN THE TREATMENT OF ENDOMETRIOSIS
SHAW, RW
DRUG SAFETY, 1994, 11 (02) : 104 - 113
[34] Risk-Benefit Assessment of Foods
Assuncao, R.
Pires, S. M.
Nauta, M.
EFSA JOURNAL, 2019, 17
[35] Sildenafil (Viagra®) -: Profile of a treatment of erectile dysfunction
Derouet, H
Jost, WH
AKTUELLE NEUROLOGIE, 2000, 27 (01) : 40 - 42
[36] Tadalafil preferred to sildenafil as treatment for erectile dysfunction
Jim Casey
Nature Clinical Practice Urology, 2006, 3 (2): : 68 - 68
[37] Sildenafil and erectile dysfunction
Fabbri, A
Aversa, A
Isidori, A
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 1999, 22 (06) : 486 - 491
[38] Sildenafil and erectile dysfunction
Lare, SB
Labbate, LA
AMERICAN JOURNAL OF PSYCHIATRY, 2000, 157 (12): : 2055 - 2056
[39] A RISK-BENEFIT ASSESSMENT OF CELIPROLOL IN THE TREATMENT OF CARDIOVASCULAR-DISEASE
KENDALL, MJ
RAJMAN, I
DRUG SAFETY, 1994, 10 (03) : 220 - 232
[40] A Risk-Benefit Assessment of Treatment with Finasteride in Benign Prostatic Hyperplasia
Peter Ekman
Drug Safety, 1998, 18 : 161 - 170

← 1 2 3 4 5 →